Log In
Print this Print this


Also known as: nitroimidazopyran

  Manage Alerts
Collapse Summary General Information
Company Global Alliance for TB Drug Development
DescriptionNitroimidazopyran with activity against both replicating and static Mycobacterium tuberculosis
Molecular Target
Mechanism of ActionBactericidal agent
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationTuberculosis
Indication DetailsTreat multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB); Treat tuberculosis (TB) infection
Regulatory Designation
PartnerNovartis AG;
Shanghai Fosun Pharmaceutical Group Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today